Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Other Events

Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Other Events
Item 9.01 Other Events.

Story continues below

On March16, 2018, Stemline Therapeutics,Inc. (the “Company”) launched an at-the-market offering (the “Offering”) of up to $50,000,000 worth of shares of the Company’s common stock, par value $0.0001 per share, to a Distribution Agreement by and among the Company, J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc., dated March16, 2018. A copy of the Distribution Agreement is attached hereto as Exhibit1.1 and is incorporated by reference herein.

Alston& Bird LLP, counsel to the Company, delivered an opinion as to the validity of the shares, a copy of which is attached hereto as Exhibit5.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.


The following exhibit is furnished as part of this report:

EX-1.1 2 a18-8294_5ex1d1.htm EX-1.1 Exhibit 1.1   DISTRIBUTION AGREEMENT   March 16,…
To view the full exhibit click here

About Stemline Therapeutics,Inc. (NASDAQ:STML)

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

An ad to help with our costs